{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(10)"],"submitter":["Kamar N"],"pubmed_abstract":["<h4>Introduction</h4>Imlifidase is authorized for desensitization of highly sensitized adult kidney transplant candidates with a positive crossmatch (XM) against a deceased donor. Here, we report on the results for the first 9 patients transplanted in this context who had at least 3 months of follow-up.<h4>Methods</h4>The eligibility criteria were as follows: calculated panel reactive antibodies (cPRA) ³ 98%, ³ 3 years on the waiting list, immunodominant donor-specific antibodies (DSAs) with mean fluorescence intensity (MFI) > 6000 (and < 5000 at 1:10 dilution) and a negative post-imlifidase complement-dependent cytotoxic XM (CDCXM).<h4>Results</h4>All 9 patients had been on dialysis for an average of 123 ± 41 months, with cPRA at 99% (<i>n</i> = 2) or 100% (<i>n</i> = 7). At transplantati"],"journal":["Kidney international reports"],"pagination":["2927-2936"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11489446"],"repository":["biostudies-literature"],"pubmed_title":["Imlifidase in Highly Sensitized Kidney Transplant Recipients With a Positive Crossmatch Against a Deceased Donor."],"pmcid":["PMC11489446"],"pubmed_authors":["Caillard S","Olagne J","Apithy MJ","Taupin JL","Pievani D","Farce F","Kamar N","Couzi L","Guidicelli GL","Bertrand D","Chauveau B","Francois A","Congy-Jolivet N","Delas A","Usureau C"],"additional_accession":[]},"is_claimable":false,"name":"Imlifidase in Highly Sensitized Kidney Transplant Recipients With a Positive Crossmatch Against a Deceased Donor.","description":"<h4>Introduction</h4>Imlifidase is authorized for desensitization of highly sensitized adult kidney transplant candidates with a positive crossmatch (XM) against a deceased donor. Here, we report on the results for the first 9 patients transplanted in this context who had at least 3 months of follow-up.<h4>Methods</h4>The eligibility criteria were as follows: calculated panel reactive antibodies (cPRA) ³ 98%, ³ 3 years on the waiting list, immunodominant donor-specific antibodies (DSAs) with mean fluorescence intensity (MFI) > 6000 (and < 5000 at 1:10 dilution) and a negative post-imlifidase complement-dependent cytotoxic XM (CDCXM).<h4>Results</h4>All 9 patients had been on dialysis for an average of 123 ± 41 months, with cPRA at 99% (<i>n</i> = 2) or 100% (<i>n</i> = 7). At transplantati","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2025-04-04T01:54:12.698Z","creation":"2025-04-04T01:54:12.698Z"},"accession":"S-EPMC11489446","cross_references":{"pubmed":["39430184"],"doi":["10.1016/j.ekir.2024.07.024"]}}